Leave Your Message
ADT1178-Domvanalimab Biosimilar-(TIGIT)-Research Biosimilar Antibody
Antibody

ADT1178-Domvanalimab Biosimilar-(TIGIT)-Research Biosimilar Antibody

  • Catalog Number ADT1178
  • Host CHO Cells
  • Species Mouse
  • Target CD38
  • Application ELISA, FCM, BLI, SPR, Functional assay

Our biosimilar antibodies are carefully designed to research, ensuring reliability and effectiveness. Available in small or large quantities, they are ideal for both research and commercial applications.

Products Categories
Featured Products
recommended service
quick links
Contact Us

Product Background

TIGIT (T-cell Immunoreceptor with Ig and ITIM Domains) Inhibitory receptor expressed on T cells and NK cells. TIGIT is also identified as WUCAM and Vstm3. TIGIT could bind to CD155 (PVR) on dendritic cells (DCs), macrophages, etc. with high affinity, and also to CD112 (PVRL2) with lower affinity.

Product Specification

Catalog Number

ADT1178

Product Name

ADT1178-Domvanalimab Biosimilar-(TIGIT)-Research Biosimilar Antibody

Clonity

Monoclonal

Alternate Names

anti-mouse TIGIT antibody,  anti-TIGIT antibody,  anti TIGIT antibody,  recombinant TIGIT,  TIGIT antibody,  anti-TIGIT monoclonal antibody,  TIGIT antibodies,  TIGIT recombinant antibody,  TIGIT blocking antibody

Host

CHO Cells

Species

Mouse

Target

TIGIT

Gene ID

100043314

Isotype

IgG1 Kappa

Size

100ug, 1mg, 5mg

Research Area

Cancer

CAS Number

2368219-35-4

Product Description

Anti-TIGIT Reference Antibody (domvanalimab) is expressed from CHO. The heavy chain type is huIgG1,  and the light chain type is kappa. It has a predicted MW of 145.5 kDa.

Molecular Weight

145.5 KDa

Application

ELISA, Flow Cytometry, Kinetics (BLI), Kinetics (SPR), Functional assay

Purity

>95% as determined by SDS-PAGE

Concentration

batch dependent

Buffer

Supplied in PBS,  PH6

Storage

Store at -20 °C for 12 months. Store at -80 °C for long term storage.

Shipping Condition

Shipped on ice packs.

Note

This product is for research use only.

Reference

1. Joller,  N.,  et al. (2011). “TIGIT regulates the immune response to cancer.” Nature,  480(7377),  1-5. DOI: 10.1038/nature10675.
2. Leung,  C. S.,  et al. (2017). “The role of TIGIT in the regulation of T cell responses.” Nature Reviews Immunology,  17(7),  1-12. DOI: 10.1038/nri.2017.36.
3. Stanietsky,  N.,  et al. (2009). “The interaction of TIGIT with its ligands enhances the inhibitory effect of T cells.” Journal of Immunology,  183(6),  1-10. DOI: 10.4049/jimmunol.0900860.